sales@dcchemicals.com
113-AA-C8C14
Formulation & Performance
Literature-reported optimized formulation B-2
| Component | Molar ratio | Role |
|---|---|---|
| 113-AA-C8C14 | 35 | Ionizable lipid |
| DOPE | 16 | Helper phospholipid |
| Cholesterol | 46.5 | Sterol lipid |
| DMG-PEG2000 | 0.5 | PEG lipid |
Ratio reporting noteThe values above are the nominal molar-ratio factors reported for formulation B-2 in Supporting Fig. S12. Their reported total is 98; the calculator below normalizes them automatically while preserving the published relative proportions.
Component molecular weights and calculated amounts
Composition retained from the cited study below. Calculation aid for research planning. DMG-PEG2000 is polydisperse; confirm the molecular weight stated for the exact material or batch. The result covers lipid component weights only and does not include RNA, buffer, solvent, process loss or N/P ratio.
| Component | Molecular weight | Molar parts | Normalized mol% | Amount (µmol) | Weight (mg) |
|---|---|---|---|---|---|
| 113-AA-C8C14 | 35.714 | 49.9398 | 55.5714 | ||
| DOPE | 16.327 | 22.8296 | 16.9860 | ||
| Cholesterol | 47.449 | 66.3486 | 25.6540 | ||
| DMG-PEG2000 | 0.510 | 0.7134 | 1.7886 |
Calculated total: 100.0000 mg lipid.
Calculated catalog planning quantities; RNA, solvent and process loss are excluded. DMG-PEG2000 uses 2507. Component mass = total lipid mass × molar parts × molecular weight / sum(parts × molecular weight). This conversion does not infer N/P.
Reported preparation contextThe four lipids were dissolved together in ethanol; mRNA was dissolved in citrate buffer at pH 4. For in vivo studies, the phases were combined with a microfluidic device at a 3:1 ethanol-to-aqueous flow-rate ratio. LNPs were dialyzed in PBS for 6 h using a 20 kDa MWCO cassette before use.
Literature-reported performance for the cited formulation
Fig. S1490.3 ± 3.0%RiboGreen assay
Fig. S1496.7 ± 1.0 nmDLS hydrodynamic size
Fig. S140.09 ± 0.05DLS
Fig. S14−16.7 ± 0.2 mVDLS
Fig. S146.66LNP value · TNS assay
Fig. S1357-foldvs Dlin-MC3-DMA spleen SORT · luciferase mRNA
Fig. S137-foldvs Dlin-MC3-DMA spleen SORT
Fig. 4 / S232.3-foldimprovement vs comparator LNP
Fig. 4H–I2.7× / 3.5×CD8+ / CD4+ infiltration vs comparator
Fig. 4C>50% at day 30comparator median survival: 22 days
Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, cell or animal model, and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetGuo Q, Zhang Y, Yang X, et al. β-Hydroxy Thioether-Derived Ionizable Lipids for Spleen-Tropic mRNA Delivery and In Vivo Chimeric Antigen Receptor T Cell Engineering. ACS Nano. 2026;20:14602–14614. DOI: 10.1021/acsnano.6c00706
Formulation: main text, Experimental Section and Supporting Figs. S11–S12. Physicochemical data: Supporting Fig. S14. In vivo performance: main Fig. 4 and Supporting Figs. S13 and S23–S36.
Formulation: main text, Experimental Section and Supporting Figs. S11–S12. Physicochemical data: Supporting Fig. S14. In vivo performance: main Fig. 4 and Supporting Figs. S13 and S23–S36.